(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback